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Modern clinical use of botulinum toxin (BoNT) by doctors requires evidence-
based facts and data to support their work. In particular, these need to be unbiased 
and complete. Too often in the past, speculative statements have been used and 
repeated until injectors have come to believe they are solid facts.1 Yet no support-
ing data exist. Consequently, doctors have often been reluctant to change to or 
even try other products because of what they have been told. This has not been 
a good situation for either clinicians or patients. We have published about these 
“urban legends”1 and tried, on many occasions, to correct these inaccuracies (see, 
for example,2,3).
Therefore the recent paper by Park and colleagues, claiming to be a review of 
a relatively new BoNT product used in blepharospasm, was disappointing at best.4 
Many of the old and outdated claims about the properties of BoNT products have 
again been repeated. In 2011, this is an incorrect approach and borders on a market-
ing activity.
For example, the product data contained in their Table 1 4 has no references 
cited as to the sources of information, is inaccurate, and does not even take into 
consideration previous publications which have highlighted errors in such tabular 
data.1 We published last year a definitive work on the formulation composition of 
BoNT products in clinical use5 specifically to stop these errors. We have previously 
suggested that authors contact manufacturers of BoNT products before they publish 
such data, to ensure complete accuracy;1 all of this has apparently been ignored by 
Park and colleagues.
Data in error in their Table 1 include the manufacturer of Myobloc®/Neurobloc® 
(this should be US WorldMeds, who acquired Solstice in August 2010), “stabilization” 
of Xeomin® (also a freeze-dried product and not as cited), the vial size of Dysport® 
(also available as 300 units per vial in many countries, including the United States), 
the vial sizes of Botox® (also available as a 50 and 200 units per vial product in many 
countries), the so-called “complex sizes” for each product (none of which exist for 
the BoNT-A products in the actual vial)6 and storage after reconstitution of Myobloc® 
(this is already liquid product and not stable “for a few hours” after reconstitution – 
which simply does not happen!)
More important clinically, Park and colleagues have published a data line report-
ing “biological activity in relation to Botox®” in their Table 1,4 citing a ratio of 1:1 for 





most contentious issue about use of BoNT-A products and 
should never be described so definitively. As the authors 
will know, the regulatory authorities around the world have 
required an insertion, in all BoNT-A product literature sup-
plied to clinicians worldwide, which clearly states that the 
units of each product are specific to that product and are 
not interchangeable. In particular, many clinicians would 
strongly argue that any “ratio” between Dysport® and Botox® 
units is more likely to be 2 or 2.5:1, respectively, and not as 
cited in their table – different reviews of many data strongly 
indicate this.
Xeomin® is stated as “being obtained from the same strain 
of Clostridium botulinum as Botox®”.4 This is incorrect. The 
statement is contradicted by a publication which specifically 
looked at the subject7 and has been corrected in relation to 
another recent publication comparing BoNT-A products 
which reported the same error.8
One of the standard reasons always given why clini-
cians should use Xeomin® is the reduced potential to raise 
BoNT neutralizing antibodies in patients. This was, indeed, 
the prime reason for initially developing the product.9 
Often, the subject of how the other proteins of the BoNT-A 
  complex (the neurotoxin associated proteins – NAPs) may 
have immunostimulating properties has been raised (see, for 
example,10).However, this has never been demonstrated, 
even experimentally in animals. Park and colleagues have 
re-stated old data from flawed studies on this subject.11 They 
have, unfortunately, dismissed careful and critical appraisal 
of those studies by the leading expert in the field of BoNT 
immunology, Professor Zouhair Atassi.10,12
There is currently no evidence that the removal of the 
BoNT-A NAPs from Xeomin® has had any beneficial effects 
on reducing BoNT-A neutralizing antibody formation in 
patients. The current immunological status for the product is 
carefully described in the current United States prescribing 
information for Xeomin® – “the potential for antibody for-
mation has not been fully characterized”.13 Statements such 
as “may reduce the risk markedly”4 are inappropriate in the 
context of critically reviewing and assessing the properties 
of a BoNT-A product for clinical use.
Indeed, Park and colleagues have cited a 17-year-old 
reference that describes the levels of antibody formation 
in patients treated with BoNT-A.14 These data originated 
from use of “old” Botox®, that is the original version of 
Botox® pre-1997, which was known to contain significant 
levels of inactive BoNT.15 The inactive BoNT promoted 
neutralizing antibody responses in patients treated with 
high doses for conditions such as cervical dystonia, accord-
ing to the treatment regimens in use at that time (typically, 
short intervals between injections, “booster” injections, 
when effects were not apparent after short periods). For 
modern clinical data dealing with blepharospasm, the 
report of Bentivoglio and colleagues16 on a large group of 
patients treated long term with BoNT reported only three 
patients (2.3%) who likely had antibodies (but also not 
determined by direct assay).
Indeed, one animal study which apparently found that 
Xeomin® raised no neutralizing antibodies under conditions 
where other BoNT-A products did, has been cited by Park 
and colleagues, namely that of Blumel et al reported actually 
in 2005.17 Unfortunately this was a poster at an international 
conference. Careful assessment of those data showed that the 
doses used of one product in the comparison were so high 
that they killed several of the test animals. The study was 
invalidated for comparative purposes.
One factor of product comparison that Park and 
  colleagues4 have used is the amount of BoNT protein that 
would be injected for each product as used in therapy. This 
is designated the “protein load” of the product, presented 
as nanograms (ng) per vial.18 The basis of their argument 
is that injecting patients with less BoNT protein per treat-
ment is a way of reducing the risk of antibody response. 
However, they have repeated, yet again, incorrect data for 
Dysport®. We have published several times over the last 
8 years clearly describing the Dysport® historic data for 
protein load over a 15-year period.18 No similar data have 
Table 1 Clinical studies reported on the use of Xeomin® for the treatment of blepharospasm
Authors Publication  
year
Patient number treated  
with Xeomin®
Comments
roggenkamper et al23 2006 129 First published use study
Jankovic et al24 2009 – Poster – pre-report of 2011 study publication25
Jankovic et al26 2009 – Development of rating scale using earlier data23
Jankovic27 2009 – review of earlier data23
Jankovic et al25 2011 75 Second published use study
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ever been published for the other BoNT-A products. The 
correct figure is 4.35 ng of Dysport® per vial, not 12.5 ng 
as Park and colleagues have cited – from a reference related 
to Xeomin®!10
But, strangely, Park et al4 have not used and compared 
data on the Xeomin® protein load per vial that have recently 
been published.19 These new data, giving 0.44 ng per vial, sig-
nificantly contradict those previously reported for Xeomin® 
of 0.6 ng per vial.10 True, these are very small amounts but 
they actually represent a significant difference as reported by 
the product manufacturer. These differences have recently 
been challenged8 but no satisfactory explanation has been 
provided in response.20 Which figure is correct? What is the 
long-term consistency of the product?
Park et al have discussed the clinical data available for the 
use of Xeomin® in blepharospasm. In fact, to my knowledge 
only six clinical papers on treatment of this condition with 
the product are listed in PubMed. Of these, one is a poster 
abstract, two repeat or re-analyze data from a   previous study, 
leaving only three studies overall (Table 1). The study by 
Wabbels and co-workers21 was not referenced by Park et al,4 
leaving only two studies with which to conduct their review. 
Over all studies, just 237 patients are reported in the litera-
ture as treated with the product since first licensure in 2005 
(Table 1). Park et al4 have also included in their review use 
of the product in other conditions such as cervical dystonia. 
Given that cervical dystonia is a large-muscle condition 
which requires large doses of BoNT-A for efficacy, certainly 
in comparison with blepharospasm, the dissimilarity between 
the conditions seems to outweigh the use of the different data 
sets for the review of use in blepharospasm. Facial muscles, 
as treated in blepharospasm, have a fundamentally different 
distribution of BoNT target neuromuscular junctions com-
pared with larger muscles of the body.22
The reader must make up their own mind as to whether 
the review appropriately deals with the subject in question. 
But issues, especially with accuracy of data cited, must also 
be taken into proper account.
Disclosure
The author declares no conflicts of interest.
References
1.  Pickett A, Caird D. Comparison of type a botulinum toxin products in 
clinical use. J Clin Pharm Ther. 2008;33(3):327–328.
2.  Pickett A, Dodd S, Rzany B. Confusion about diffusion and the art 
of misinterpreting data when comparing different botulinum toxins 
used in aesthetic applications. J Cosmet Laser Ther. 2008;10(3): 
181–183.
  3.  Pickett A. Dysport®: Pharmacological properties and factors that 
  influence toxin action. Toxicon. 2009;54(5):683–689.
  4.  Park J, Lee MS, Harrison AR. Profile of Xeomin® (incobotulinum-
toxinA) for the treatment of blepharospasm. Clin Ophthalmol. 2011;5: 
725–732.
  5.  Pickett A, Perrow K. Formulation composition of botulinum toxins in 
clinical use. J Drugs Dermatol. 2010;9(9):1085–1091.
  6.  Eisele K-H, Fink K, Vey M, Taylor HV . Studies on the dissociation 
of botulinum neurotoxin type A complexes. Toxicon. 2011;57(4): 
555–565.
  7.  Fang P-K, Raphael B, Maslanka S, Cai S, Singh B. Analysis of genomic 
differences among Clostridium botulinum type A1 strains. BMC 
  Genomics. 2010;11(1):725.
  8.  Pickett A. Consistent Biochemical data are essential for comparability 
of botulinum toxin type A products. Drugs R D. 2011;11(1):97–98.
  9.  Dressler D. Routine use of Xeomin® in patients previously treated with 
Botox: long term results. Eur J Neurol. 2009;16 Suppl 2:2–5.
  10.  Frevert J. Xeomin® is free from complexing proteins. Toxicon. 2009; 
54(5):697–701.
  11.  Lee JC, Yokota K, Arimitsu H, et al. Production of anti-neurotoxin 
antibody is enhanced by two subcomponents, HA1 and HA3b, of 
Clostridium botulinum type B 16S toxin-haemagglutinin. Microbiology. 
2005;151(Pt 11):3739–3747.
  12.  Atassi MZ. On the enhancement of anti-neurotoxin antibody produc-
tion by subcomponents HA1 and HA3b of Clostridium botulinum 
type B 16S toxin-haemagglutinin. Microbiology. 2006;152(Pt 7): 
1891–1895.
  13.  Xeomin® prescribing information http://www.accessdata.fda.gov/
drugsatfda_docs/label/2010/125360lbl.pdf. Accessed July 19, 2011.
  14.  Greene P, Fahn S, Diamond B. Development of resistance to botu-
linum toxin type A in patients with torticollis. Mov Disord. 1994; 
9(2):213–217.
  15.  Borodic G, Johnson E, Goodnough M, Schantz E. Botulinum toxin 
therapy, immunologic resistance, and problems with available materials. 
Neurology. 1996;46(1):26–29.
  16.  Bentivoglio AR, Fasano A, Ialongo T, Soleti F, Lo FS, Albanese A.     
Fifteen-year experience in treating blepharospasm with Botox or   
Dysport: same toxin, two drugs. Neurotox Res. 2009;15(3):224–231.
  17.  Blumel J, Frevert J, Schwaier A. Comparative antigenicity of three 
preparations of botulinum neurotoxin type A in the rabbit. Paper 
presented at: 5th Triennial International Conference on Basic and 
Therapeutic Aspects of Botulinum and Tetanus Toxins (Toxins 2005) 
2005; Denver, Colorado, USA.
  18.  Panjwani N, O’Keeffe R, Pickett AM. Biochemical, functional and 
potency characteristics of type A botulinum toxin in clinical use. The 
Botulinum Journal. 2008;1(1):153–166.
  19.  Frevert J. Content of botulinum neurotoxin in Botox®/Vistabel®, 
Dysport®/Azzalure®, and Xeomin®/Bocouture®. Drugs R D. 2010; 
10(2):67–73.
  20.  Frevert J. Author’s Reply. Drugs R D. 2011;11(1):98–99.
  21.  Wabbels B, Reichel G, Fulford-Smith A, Wright N, Roggenkamper P. 
Double-blind, randomised, parallel group pilot study comparing two 
botulinum toxin type A products for the treatment of blepharospasm. 
J Neural Transm. 2011;118(2):233–239.
  22.  Happak W, Liu J, Burggasser G, Flowers A, Gruber H, Freilinger G. 
Human facial muscles: dimensions, motor endplate distribution, and 
presence of muscle fibers with multiple motor endplates. Anat Rec. 
1997;249(2):276–284.
  23.  Roggenkamper P, Jost WH, Bihari K, Comes G, Grafe S. Efficacy and 
safety of a new Botulinum Toxin Type A free of complexing proteins 
in the treatment of blepharospasm. J Neural Transm. 2006;113(3): 
303–312.
  24.  Jankovic J, Comella C, Hanschmann A, Grafe S. Efficacy and safety 
of NT 201 (botulinum neurotoxin free from complexing proteins) in 
blepharospasm. Paper presented at: American Academy of Neurology 
61st Annual Meeting 2009; Seattle, WA.Clinical Ophthalmology
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/clinical-ophthalmology-journal
Clinical Ophthalmology is an international, peer-reviewed journal 
covering all subspecialties within ophthalmology. Key topics include: 
Optometry; Visual science; Pharmacology and drug therapy in eye 
diseases; Basic Sciences; Primary and Secondary eye care; Patient 
Safety and Quality of Care Improvements. This journal is indexed on 
PubMed Central and CAS, and is the official journal of The Society of 
Clinical Ophthalmology (SCO). The manuscript management system 
is completely online and includes a very quick and fair peer-review 
system, which is all easy to use. Visit http://www.dovepress.com/ 
testimonials.php to read real quotes from published authors.






  25.  Jankovic J, Comella C, Hanschmann A, Grafe S. Efficacy and 
safety of incobotulinumtoxinA (NT 201, Xeomin®) in the treatment 
of   blepharospasm – a randomized trial. Mov Disord. 2011;26(8): 
1521–1528.
  26.  Jankovic J, Kenney C, Grafe S, Goertelmeyer R, Comes G.   Relationship 
between various clinical outcome assessments in patients with blephar-
ospasm. Mov Disord. 2009;24(3):407–413.
  27.  Jankovic J. Clinical efficacy and tolerability of Xeomin® in the treatment 
of blepharospasm. Eur J Neurol. 2009;16:14–18.